The $500 Million Shortcut That Bought a Billion-Dollar Biotech
Sino Biopharmaceutical is acquiring LaNova Medicines for up to $951 million, but the real story is in the math: Merck already paid $588 million for just one of LaNova's drugs. The deal spotlights the red-hot bispecific antibody gold rush reshaping oncology dealmaking.
Sino Biopharmaceutical just bought an entire cancer biotech for less than what Merck paid for a single one of its drugs.
Let that math sink in for a second. Merck handed LaNova Medicines $588 million upfront last year for global rights to one bispecific antibody. Now Sino Biopharm is scooping up the whole company, every asset, every platform, every scientist, for a net cost of roughly $500 million. The headline price says $951 million, but LaNova is sitting on about $450 million in cash. So the actual check Sino writes? About half a billion.
It's like buying a house that has a safe full of cash in the basement. You're technically paying list price, but you're getting most of the money back at closing.
Why LaNova Was the Hottest Ticket in Shanghai
LaNova Medicines isn't a household name, but it's been quietly assembling one of the most impressive dance cards in Chinese biotech. Founded in 2019 by Dr. Crystal Qin, the Shanghai-based company built three proprietary technology platforms focused on antibody-based cancer treatments. Think of it as a factory that produces different flavors of cancer-fighting molecules: traditional antibodies, antibody-drug conjugates (ADCs, which are essentially guided missiles that deliver chemo directly to tumors), and bispecific antibodies.
Bispecific antibodies are the star of this story, so let's make sure they click. A normal antibody is like a key that fits one lock. A bispecific antibody is a Swiss Army knife: it grabs two different targets at once. In LaNova's case, their flagship bispecific LM-299 latches onto both PD-1 (an immune checkpoint that tumors exploit to hide from your immune system) and VEGF (a protein that tumors use to grow new blood vessels and feed themselves). Block both at the same time, and you're hitting cancer with a one-two punch.
That dual-target approach caught Merck's attention in late 2024. The resulting deal: $588 million upfront, with potential milestones reaching $2.7 billion across multiple cancer types. Total deal value north of .
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
$3.2 billion
And Merck wasn't LaNova's only suitor. AstraZeneca had already licensed LaNova's GPRC5D-targeting ADC (called LM-305, aimed at multiple myeloma) for $55 million upfront and up to $545 million in milestones. Add it all up, and LaNova had racked up nearly $4 billion in cumulative licensing value before most biotech investors even knew its name.
The Bispecific Gold Rush
Sino Biopharm isn't buying LaNova in a vacuum. The entire biopharma world is in a frenzy over PD-1/VEGF bispecifics right now, and the price tags tell the story.
Pfizer paid $1.25 billion upfront to 3SBio for a PD-1/VEGF bispecific in May 2025. AbbVie dropped $650 million upfront on RemeGen's version in January 2026. Bristol Myers Squibb partnered with BioNTech on a PD-L1/VEGF bispecific in a deal worth up to $11.1 billion. And Genmab is acquiring Merus, which makes bispecific oncology antibodies, for about $8 billion.
What's driving all this? One drug, mostly. Ivonescimab, a PD-1/VEGF bispecific made by China's Akeso (and licensed globally to Summit Therapeutics), beat Merck's blockbuster Keytruda head-to-head in a Phase III lung cancer trial. That result sent shockwaves through the industry. If a bispecific can outperform the world's best-selling cancer drug, every pharma company needs one in its portfolio.
Phase 2 bispecific oncology deals now command median upfronts of $257 million, roughly three times what traditional antibody deals fetch at the same stage. Royalty rates sit between 9% and 19%, among the highest in oncology licensing.
And there's a geographic wrinkle worth noting: a disproportionate number of these assets originate from Chinese biotechs. LaNova, Akeso, 3SBio, RemeGen, Innovent, Biotheus; the list keeps growing. China has become the R&D engine for bispecifics, with Western pharma writing the checks to commercialize globally.
What Sino Biopharm Actually Gets
Sino Biopharmaceutical, a Hong Kong-listed Chinese pharma group, already owned a small 4.91% stake in LaNova from a Series C1 investment in late 2024. This deal picks up the remaining 95.09%, making LaNova a wholly owned subsidiary.
The payment structure reveals some smart financial engineering. Not all $951 million gets paid at once. Part of the consideration is deferred and contingent: some payments depend on employees and founders staying with the company post-deal, while others are tied to LaNova hitting specific milestones, including progress on the LM-299 program with Merck. It's a retention and performance mechanism baked into the acquisition price.
Beyond LM-299 and LM-305, Sino picks up a deep bench of clinical-stage assets. There's a CCR8 antibody in a Phase 2 trial in China, a Claudin 18.2 ADC in Phase 3, and several earlier-stage programs spanning everything from SIRPα to CTLA-4 to 4-1BB bispecifics. Nearly 20 early-stage pipeline assets round out the portfolio.
Sell-side analysts are on board. The rationale: LaNova's globally validated licensing track record makes future out-licensing deals more visible and more valuable.
PharmCube called this the largest domestic pharma M&A deal in China's history by valuation, and the fourth-largest acquisition of a Chinese drug company overall.
The Math That Makes It Click
The bull case writes itself when you look at the numbers from Sino Biopharm's perspective. The company is paying roughly $500 million net for a biotech whose single biggest asset already commanded $588 million upfront from Merck. That means Sino is essentially acquiring LaNova's entire remaining pipeline, its platforms, and its team for a negative net price once you account for the Merck deal economics.
Industry observers flagged the obvious risk, though: most of LaNova's core assets are still early stage. The company reported just RMB 216,000 in revenue in 2024 (that's roughly $30,000; barely enough to cover a month of lab supplies). Sino is buying potential, not profits.
But that's the nature of biotech M&A in 2026. You're not paying for what a company earns today. You're paying for the probability that its science works tomorrow. And when the science involves bispecific antibodies targeting PD-1 and VEGF, the entire industry is betting those probabilities are worth billions.
Seven years from founding to a near-billion-dollar exit. For Dr. Crystal Qin and the LaNova team, the bet on bispecifics paid off. For Sino Biopharm, the bet is just getting started.
Deals & M&A5 min read
GSK Just Lit $700 Million on Fire (and Walked Away)
GSK just terminated its $2.2 billion Alzheimer's partnership with Alector after both drugs flopped in clinical trials. The $700 million upfront payment is gone forever, and the wreckage tells us a lot about why the brain remains drug development's toughest frontier.
